Xavier Leleu,for the Intergroupe Francophone du Myélome (IFM),Lionel Karlin,for the Intergroupe Francophone du Myélome (IFM),Margaret Macro,for the Intergroupe Francophone du Myélome (IFM),Cyrille Hulin,for the Intergroupe Francophone du Myélome (IFM),Laurent Garderet,for the Intergroupe Francophone du Myélome (IFM),Murielle Roussel,for the Intergroupe Francophone du Myélome (IFM),Bertrand Arnulf,for the Intergroupe Francophone du Myélome (IFM),Brigitte Pegourie,for the Intergroupe Francophone du Myélome (IFM),Brigitte Kolb,for the Intergroupe Francophone du Myélome (IFM),Anne Marie Stoppa,for the Intergroupe Francophone du Myélome (IFM),Sabine Brechiniac,for the Intergroupe Francophone du Myélome (IFM),Gerald Marit,for the Intergroupe Francophone du Myélome (IFM),Beatrice Thielemans,for the Intergroupe Francophone du Myélome (IFM),Brigitte Onraed,for the Intergroupe Francophone du Myélome (IFM),Claire Mathiot,for the Intergroupe Francophone du Myélome (IFM),Anne Banos,for the Intergroupe Francophone du Myélome (IFM),Laurence Lacotte,for the Intergroupe Francophone du Myélome (IFM),Mourad Tiab,for the Intergroupe Francophone du Myélome (IFM),Mamoun Dib,for the Intergroupe Francophone du Myélome (IFM),Jean-Gabriel Fuzibet,for the Intergroupe Francophone du Myélome (IFM),Marie Odile Petillon,for the Intergroupe Francophone du Myélome (IFM),Philippe Rodon,for the Intergroupe Francophone du Myélome (IFM),Marc Wetterwald,for the Intergroupe Francophone du Myélome (IFM),Bruno Royer,for the Intergroupe Francophone du Myélome (IFM),Laurence Legros,for the Intergroupe Francophone du Myélome (IFM),Lotfi Benboubker,for the Intergroupe Francophone du Myélome (IFM),Olivier Decaux,for the Intergroupe Francophone du Myélome (IFM),Martine Escoffre-Barbe,for the Intergroupe Francophone du Myélome (IFM),Denis Caillot,for the Intergroupe Francophone du Myélome (IFM),Jean Paul Fermand,for the Intergroupe Francophone du Myélome (IFM),Philippe Moreau,for the Intergroupe Francophone du Myélome (IFM),Michel Attal,for the Intergroupe Francophone du Myélome (IFM),Herve Avet-Loiseau,for the Intergroupe Francophone du Myélome (IFM),Thierry Facon,for the Intergroupe Francophone du Myélome (IFM)

View Articletitled, Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium

Il Ho Jang,Yi-Fen Lu,Long Zhao,Pamela L. Wenzel,Tsutomu Kume,Sumon M. Datta,Natasha Arora,Jordi Guiu,Mounia Lagha,Peter G. Kim,Eun Kyoung Do,Jae Ho Kim,Thorsten M. Schlaeger,Leonard I. Zon,Anna Bigas,Caroline E. Burns,George Q. Daley

View Articletitled, Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium

Supplemental data

IMMUNOBIOLOGY

A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice

Fernando E. Sepulveda,Sophia Maschalidi,Christian A. J. Vosshenrich,Alexandrine Garrigue,Mathieu Kurowska,Gael Ménasche,Alain Fischer,James P. Di Santo,Geneviève de Saint Basile

View Articletitled, A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice

Supplemental data

LYMPHOID NEOPLASIA

Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma

Yuanshen Huang,Ming-Wan Su,Xiaoyan Jiang,Youwen Zhou

View Articletitled, Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma

Supplemental data

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL

Iris Appelmann,Cory D. Rillahan,Elisa de Stanchina,Gregory Carbonetti,Chong Chen,Scott W. Lowe,Charles J. Sherr

View Articletitled, Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL

Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production

Alberto Yáñez,Madelena Y. Ng,Nargess Hassanzadeh-Kiabi,Helen S. Goodridge

View Articletitled, IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production

Supplemental data

PLATELETS AND THROMBOPOIESIS

Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation

Sami Albeiroti,Katayoun Ayasoufi,David R. Hill,Bo Shen,Carol A. de la Motte

View Articletitled, Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation

Supplemental data

Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality
Clinical Trials & Observations

Ruchika Goel,Paul M. Ness,Clifford M. Takemoto,Lakshmanan Krishnamurti,Karen E. King,Aaron A. R. Tobian

View Articletitled, Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes

Shuaiying Cui,Osamu Tanabe,Michael Sierant,Lihong Shi,Andrew Campbell,Kim-Chew Lim,James Douglas Engel

View Articletitled, Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes

Supplemental data

THROMBOSIS AND HEMOSTASIS

Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor

Cristina Puy,Erik I. Tucker,Anton Matafonov,Qiufang Cheng,Keith D. Zientek,Dave Gailani,András Gruber,Owen J. T. McCarty

View Articletitled, Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor

Supplemental data

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation
Brief Report

Yesim Dargaud,Jean Yves Scoazec,Simone J. H. Wielders,Christine Trzeciak,Tilman M. Hackeng,Claude Négrier,H. Coenraad Hemker,Theo Lindhout,Elisabetta Castoldi

View Articletitled, Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation

TRANSPLANTATION

Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo
Brief Report

Simrit Parmar,Xiaoying Liu,Amer Najjar,Nina Shah,Hong Yang,Eric Yvon,Katy Rezvani,Ian McNiece,Patrick Zweidler-McKay,Leonard Miller,Steve Wolpe,Bruce R. Blazar,Elizabeth J. Shpall

View Articletitled, Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo

Supplemental data

BLOOD WORK

Unwelcome passengers

Armin Rashidi,Stephen I. Fisher

View Articletitled, Unwelcome passengers

Cover Image

Cover Image

Smooth muscle cells produce a pathological hyaluronan matrix (green) typified by cable-like structures when activated with the viral mimetic polyI:C or a number of other agents. Platelets (immunohistochemically stained red for CD42b) have the ability to bind to hyaluronan cables. Additionally, they carry the hyaluronan-degrading enzyme HYAL2 in their α granules. Upon activation, platelets rapidly transpose the enzyme to their surface, thus putting enzyme and substrate in close proximity. This results in hyaluronan matrix degradation. In this experiment, hyaluronan removal is blocked with any antibody to HYAL2. See the article by Albeiroti et al on page 1460.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Licking the wound with procoagulant vesicles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

CAR T-cells in autoimmunity: game changer or stepping stone?

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

CD30: seeing is not always believing Clinical Trials & Observations

Treatment of primary CNS lymphoma Clinical Trials & Observations

PLENARY PAPER

PERSPECTIVES

BLOOD SPOTLIGHT

HOW I TREAT

How I use fibrinogen replacement therapy in acquired bleeding Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Clinical Trials & Observations

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma Clinical Trials & Observations

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

PLATELETS AND THROMBOPOIESIS

Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality Clinical Trials & Observations

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation Brief Report

TRANSPLANTATION

Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo Brief Report

BLOOD WORK

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

CD30: seeing is not always believing
Clinical Trials & Observations

Treatment of primary CNS lymphoma
Clinical Trials & Observations

How I use fibrinogen replacement therapy in acquired bleeding
Clinical Trials & Observations

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Clinical Trials & Observations

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Clinical Trials & Observations

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Clinical Trials & Observations

Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality
Clinical Trials & Observations

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation
Brief Report

Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo
Brief Report